Bioactivity | Mocravimod hydrochloride (KRP-203), an immunosuppressant, is a potent and orally active S1PR1 (sphingosine 1-phosphate receptor type 1) agonist[1][2]. |
Target | S1PR1 |
In Vivo | Mocravimod hydrochloride (KRP-203) ameliorates atherosclerosis in LDL-R−/− Mice[1]. Mocravimod hydrochloride (KRP-203) (orally; 0.1 and 1 mg/kg/day; for 100 days) prolongs graft survival and attenuates chronic rejection in mHC-disparate rat heart allografts[2]. Animal Model: |
Name | Mocravimod hydrochloride |
CAS | 509088-69-1 |
Formula | C24H27Cl2NO3S |
Molar Mass | 480.45 |
Appearance | Solid |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Reference | [1]. Potì F, et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1505-12. [2]. Shimizu H, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronicrejection in rat skin and heart allografts. Circulation. 2005 Jan 18;111(2):222-9. Epub 2005 Jan 10. |